New Prague, Minnesota--(Newsfile Corp. - November 20, 2025) - Electromed, Inc. (NYSE American: ELMD) ("Electromed" or the "Company"), a leader in innovative airway clearance technologies, today announced that it will participate in NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference being held at Florida Atlantic University in Boca Raton, Florida, on Wednesday, December 3, 2025. Jim Cunniff, Electromed's President and Chief Executive Officer, will present at 5:00 pm ET ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, Nov. 17th:Roku (ROKU) : This company, which is the leading TV streaming platform provider in the United States, Canada and Mexico, has a Zacks Rank #1 (Strong Buy), and witnessed the Zacks Consensus Estimate for its current year earnings increasing 83.3% over the last 60 days.Roku's shares gained 8% over the last three month compared with the S&P 500’s gain of 4.5%. The company possesses a Momentum Score ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the tr ...

Core Viewpoint - Electromed, Inc. (ELMD) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of changing earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine a company's fair value, leading to buying or selling actions that affect stock prices [4]. Recent Performance and Outlook - Electromed's earnings estimates have seen a 7% increase over the past three months, with an expected earnings per share of $1.07 for the fiscal year ending June 2026, indicating stability year-over-year [8]. - The upgrade reflects an improvement in Electromed's underlying business, which is likely to attract investor interest and push the stock price higher [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - Historically, Zacks Rank 1 stocks have generated an average annual return of +25% since 1988, showcasing the effectiveness of the rating system [7].

Core Viewpoint - Electromed, Inc. (ELMD) shares have increased by 8.4% in the past four weeks, closing at $26.35, with a potential upside of 39.2% based on Wall Street analysts' mean price target of $36.67 [1][4]. Price Targets - The average price target for ELMD ranges from a low of $36.00 to a high of $38.00, with a standard deviation of $1.15, indicating a relatively tight clustering of estimates [2][9]. - The lowest estimate suggests a 36.6% increase from the current price, while the highest estimate indicates a 44.2% upside [2]. Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher, which historically correlates with positive stock price movements [4][11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 2.9%, with two estimates moving higher and no negative revisions [12]. Zacks Rank - ELMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a solid potential upside [13]. Conclusion on Price Targets - While the consensus price target may not be a reliable predictor of the exact price movement, it does provide a useful directional guide for potential stock performance [14].

Group 1 - The article does not provide any specific content related to a company or industry [1]

Financial Performance - Net revenues for the three months ended September 30, 2025, were $16,887,000, an increase of 15.1% compared to $14,668,000 for the same period in 2024[60] - Homecare revenue increased by $1,678,000 or 12.7%, primarily due to an increase in direct sales representatives and higher net revenues per sales representative[61] - Hospital revenue was $1,047,000, an increase of 51.7%, reflecting an increase in sales representatives focused on the hospital market[62] - Gross profit increased to $13,197,000, or 78.1% of net revenues, compared to $11,491,000, or 78.3% of net revenues in the prior year[65] - Operating income increased by $732,000 or 37.8% to $2,670,000 for the three months ended September 30, 2025[72] - Net income for the three months ended September 30, 2025, was $2,136,000, an increase of 44.9% compared to $1,474,000 for the same period in 2024[76] Expenses and Cash Flow - Research and development expenses were $241,000, an increase of 45.2% compared to the same period in the prior year, primarily due to increased headcount and external spend[71] - Cash flows from operating activities were $169,000, consisting of net income of $2,136,000 and non-cash expenses of $717,000[77] Liquidity and Financial Resources - The company maintains a credit facility with a maximum borrowing limit of $2,500,000, which was fully available as of September 30, 2025[81] - The company expects its working capital of approximately $35,800,000 to be sufficient to meet anticipated liquidity needs for the next twelve months[80] Regulatory and Market Risks - The company emphasizes the importance of maintaining reimbursement from Medicare, Medicaid, and private insurance payers for its products[88] - The company faces risks related to component or raw material shortages, significant price increases, and changes to trade regulations[88] - The company acknowledges the potential impact of adverse economic conditions and intense competition on its operations[88] - The company recognizes the potential entry of new competitors and adverse changes in healthcare regulations as significant risks[88] Strategic Focus and Development - The company is focused on developing new sales channels, including hospital and homecare distributor channels[88] - The company anticipates ongoing compliance with regulatory requirements and aims to gain future regulatory approvals[88] - The company is committed to protecting and expanding its intellectual property portfolio[88] Cybersecurity and Operational Challenges - The company highlights the risks associated with cyberattacks and data breaches that could affect its operations[88] - The company is aware of the challenges posed by wage inflation and technical problems with its research and products[88] Forward-Looking Statements - The company does not undertake any obligation to update forward-looking statements unless required by law[87]

Revenue Growth - Net revenues increased by 15.1% to $16.9 million in Q1 FY 2026, compared to $14.7 million in Q1 FY 2025[5] - Direct homecare revenue grew by 12.7% to $14.9 million, driven by an increase in direct sales representatives and higher net revenues per representative[6] - Non-homecare revenue reached $2.0 million, with hospital revenue growing by 51.7% to $1,047,000 and homecare distributor revenue increasing by 41.2% to $829,000[7] Profitability - Gross profit rose to $13.2 million, representing 78.1% of net revenues, compared to 78.3% in the prior year[8] - Operating income increased by 37.8% to $2.7 million, or 15.8% of net revenues, compared to $1.9 million, or 13.2% of net revenues in Q1 FY 2025[11] - Net income was $2.1 million, or $0.25 per diluted share, reflecting a 44.9% increase from $1.5 million, or $0.16 per diluted share in the prior year[9] Expenses - Selling, general and administrative expenses rose by 9.6% to $10.3 million, primarily due to increased salaries and personnel in sales and support teams[10] - Depreciation expenses rose to $214,000 from $202,000, reflecting an increase of approximately 5.94%[22] - Share-based compensation expense decreased to $458,000 from $697,000, a decline of about 34.34%[22] Cash Flow and Financial Position - As of September 30, 2025, Electromed had $14.1 million in cash and no debt, achieving total shareholders' equity of $44.7 million[12] - Net cash provided by operating activities decreased to $169,000 from $2,309,000 year-over-year, indicating a decline of about 92.65%[22] - Cash used for investing activities increased to $267,000 compared to $58,000 in the prior year, reflecting a rise of approximately 360.34%[22] - Cash used for financing activities was $1,076,000, a decrease from $4,467,000 in the previous year, showing a reduction of about 76.14%[22] - Cash and cash equivalents at the end of the period were $14,113,000, compared to $13,864,000 at the end of the same period in 2024, showing a slight increase of about 1.80%[22] - The company experienced a net decrease in cash of $1,174,000, compared to a decrease of $2,216,000 in the same quarter of the previous year, indicating an improvement of approximately 47.00%[22] Stock and Corporate Actions - The company completed its manufacturing optimization plan and implemented a new CRM system to enhance sales productivity[3] - Electromed's board approved a stock repurchase authorization of $10 million in Q1 FY 2026[9] - The company repurchased common stock amounting to $1,003,000, down from $4,536,000 in the same quarter last year, indicating a decrease of approximately 77.92%[22] Accounts Receivable - Accounts receivable showed a significant change, decreasing by $96,000 compared to an increase of $967,000 in the previous year[22]

Electromed, Inc. Investor Presentation November 12, 2025 NYSE American: ELMD Innovation Leader in Airway Clearance Technologies Investor Presentation | 2 Electromed – Who We Are Electromed, Inc. is a growing medical device company focused on airway management to help people around the world breathe better, stay healthier, and lead active and fulfilling lives. *As of and for 12 months ended 9/30/2025 Key Stats: Headquarters: New Prague, MN Ticker: ELMD Established: 1992 Annual Revenue: $66.2M* Market Cap: $2 ...

Core Points - Electromed, Inc. will participate in the LD Micro Main Event XIX Conference from October 19-21, 2025, in San Diego [2] - The presentation by Electromed's President and CEO, Jim Cunniff, is scheduled for October 20 at 10:00 am PT [2] - A live webcast of the presentation will be available, and the link will be posted on the Electromed Investor Relations website [2] Company Overview - Electromed, Inc. specializes in manufacturing, marketing, and selling airway clearance therapy products, including the SmartVest® Airway Clearance System [4] - The company is headquartered in New Prague, Minnesota, and was founded in 1992 [4] - Additional information about Electromed can be found on their website [4]